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Abstract
Purpose: To decrease the number of missed opportunities for human papillomavirus vaccine
eligible patients seeking healthcare in a Nurse Managed Health Center. Background &
Significance: Human papillomavirus genital infection has inflicted nearly 79 million Americans.
Annually, about 14 million newly infected individuals are identified, with noted predominance in
teens and young adults, and of this number approximately 19,200 females and 11,600 males
receive a cancer diagnosis as a result of the human papillomavirus infection. The incidence of
infections can be reduced with a human papillomavirus vaccine, but only about 63% of females
and even fewer males initiate the human papillomavirus vaccine. Methods: A Nurse Managed
Health Center assisting the underserved population, in a major southwestern metropolitan city
was chosen to implement a Qualified Patient Prompter tool used to screen for human
papillomavirus eligibility in all patients seeking healthcare in this Nurse Managed Health Center.
A reminder card strategy was used at the end of the accepted human papillomavirus vaccine
visit. Results: 334 patient records were reviewed and 135 were eligible to receive the human
papillomavirus vaccine; 60 opted to receive it and 75 declined. Conclusion: A 100% of all
patients seen were evaluated for human papillomavirus vaccine eligibility. The intervention
decreased missed opportunities by 100%. Continued efforts will focus on increasing human
papillomavirus vaccine acceptance rates. The Nurse Managed Health Center fully support the
continued use of the Qualified Patient Prompter, which was effective within this population.
Keywords: HPV, HPV Vaccine, HPV Guidelines, Provider reminder, HPV intervention
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The human papillomaviruses (HPV) are classified as typical and have as many as 120
various strains. The bulk of the different kinds of HPV strains have been detected as infecting the
body’s cutaneous and mucosal epithelial cells. The warts that occur on the cutaneous surfaces of
hands and feet have been linked with most HPV infections. An estimated 40 HPVs infections
have been associated with infecting the genitals, mouth, plus the throat’s mucosal epithelial cells.
The majority of these HPV infections are categorized as asymptomatic, undetectable and/or
spontaneously dissolving (Centers for Disease Control and Prevention, 2016b; Khan, 2017). Yet,
some persistent HPV infections can lead to cancer, which are predominately the HPV forms 16,
18, 31, 33,45, 52, and 58 (Centers for Disease Control and Prevention, 2016b; Khan, 2017;
Saraiya et al., 2015).
The HPV 16 and 18 are forms commonly associated with recurrent, high-risk (oncogenic)
infections. These HPV 16 and 18 types are affiliated with cervical, vaginal, as well as vulvar
cancers in women plus penile cancers among men; and in both males and females, malignancies
within the oropharyngeal and anal cancers have been identified with the HPV 16 and18 forms
(Centers for Disease Control and Prevention, 2016b; Khan, 2017; Saraiya et al., 2015).
The HPV 6 and 11 are common low-risk (non-oncogenic) forms associated with genital
warts and infrequent laryngeal papillomas. HPV 6 and 11 may also produce benign and/or lowgrade cervical cell irregularities. Within the United States, the most frequently shared sexually
transmitted infection, remains HPV (Centers for Disease Control and Prevention, 2016b, 2014;
Saraiya et al., 2015).
HPV genital infections have inflicted nearly 79 million Americans. Every year
individuals that are recognized as newly infected amount to roughly 14 million, and the
prevalence is particularly high in teens and young adults. The United States, yearly estimation
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results are that 30,800 individuals (11,600 males and 19,200 females) are diagnosed with cancer
caused by an HPV infection (Centers for Disease Control and Prevention, 2016b). Seventy
percent of all cervical cancer cases are the results of HPV variants 16 and 18, with roughly
12,000 females being newly diagnosed and 4,400 deaths associated with this cancer occurring
yearly within the United States. For our nation’s men with HPV 16, diagnoses of oropharyngeal
cancer are common. Anogenital cancer is another cancer linked with HPV 16 form (Centers for
Disease Control and Prevention, 2016c, 2017c; Khan, 2017; Saraiya et al., 2015). A focus on the
prevention of the HPV infection is vital. In this southwestern state, the yearly expense for HPVlinked diseases among males and females approached $170 million (The University of Texas
MD Anderson Cancer Center, 2017).
Statement of the Problem
HPV is recognized as the most frequently occurring sexually transmitted infection.
Almost all individuals engaging in sexual activity and/or intimately touching skin to skin will be
exposed at some point within their lifetime to HPV (Centers for Disease Control and Prevention,
2017c). HPV has multiple strains, of which genital warts (HPV 6 and 11) and various cancers
(HPV 16 and 18) have been associated. Vaccines are available to combat these viruses, but
vaccination rates remain low (Centers for Disease Control and Prevention, 2017c; Saraiya et al.,
2015, The University of Texas MD Anderson Cancer Center, 2017).
In the major metropolitan city in Texas selected as the site for this project, the estimated
vaccination coverage with greater than 1 dose of HPV vaccine for females, 13-17 years of age
presented approximation of 47.7% and 50.7 % for the state. The male adolescents within the
same age bracket have an estimated vaccine coverage for greater than 1 dose of HPV
immunization of approximately 35.6% at the county level and 36.6% at the state level (Centers
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for Disease Control and Prevention, 2015). The HPV vaccine rate for the Nurse Manage Health
Center (NMHC), site of the proposed project, is 14.1% for males and 19.2% for females, for an
overall total of 33.3% for patients 9-26 years of age. These figures indicate that local and state
HPV vaccine rates are well below the Healthy People 2020 target goal of 80% for females and
males 13 to 15 years old (Healthy People 2020, 2017b, 2017c).
Background and Significance
During a 4-year period (2009–2013), 29,800 HPV16 and 18 related cancer cases were
identified (Centers for Disease Control and Prevention, 2017a; Hariri et al., 2015). Yet, an HPV
vaccine approved by the U. S. Food and Drug Administration (FDA) has been available since
2006 (FDA, 2016).
The vaccine was originally developed as a HPV bivalent vaccine targeting the HPV
forms 16 and 18 for females ages 9 through 25 years. The present day, human papillomavirus 9valent vaccine, known as Gardasil 9, is effective in preventing conditions caused by HPV types
16,18,31,33,45,52, and 58; all prevalent oncogenic viruses identified in cervical vulvar, vaginal,
and anal cancers. In addition, the vaccine is effective against HPV types 6 and 11, identified in
genital warts (condyloma acuminata). The vaccine is designated for girls, women, boys, and men
from 9 to 26 years of age (FDA, 2016).
A national 2015 survey, established that 13 to 17-year-old females had a rate of 63% for
initiating the HPV vaccine dose number one; but only 42% of these individuals completed the
three-dose series. The males’ HPV initiation was lower. The uptake rate in 13-17-year-old males
was 50%, with merely 25% receiving the recommended 3-dose series (Centers for Disease
Control and Prevention, 2016a).
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The literature provides clear evidence for the efficacy of the HPV vaccine in reducing
high grade cervical lesions and emphasizes the importance of recommending and providing the
vaccine to all patients falling within the parameters for eligibility. Importantly, investigators have
found that the greatest uptake of the vaccine occurs when it is recommended by healthcare
providers, initiating the HPV vaccine at a younger age, along with making use of educational and
reminder strategies with parents whose children are eligible for HPV vaccine initiation (Cassidy,
Braxter, Charron-Prochownik, & Schlenk, 2014; Perkins et al., 2015; Rahman, Laz, McGrath, &
Berenson, 2015; St. Sauver et al., 2016).
Organizational Assessment
The NMHC is a non-profit organization in a major southwestern metropolitan city in the
United States. The NMHC’s location is within a section associated with unemployment plus
unstable economic security. Poverty, limited educational opportunities, unreasonable housing
market costs, and public safety concerns are all identifiable within the community surrounding
the clinic (City of San Antonio, 2016). The clinic had just observed its one year anniversary of
operations. The NMHC has successfully positioned itself to provide healthcare services to the
vulnerable populations within its community.
This NMHC’s healthcare organization is an extension of a meso-system of a larger,
respected leader in education and established learning institute. The patients’ healthcare is
delivered with adherence to the standards of care guidelines, along with following the set
guidelines and the mission statement for the institution’s mesosystem aspect targeting a healing
ministry aspect (University of the Incarnate Word, 2016).
The purpose of the needs assessment is to determine an organization’s readiness for
change, the need for change, and clarify resources and alternatives. The assessment helps to
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identify gaps in the institution’s current versus intended state. The needs assessment sets the
foundation for establishing goals and the necessary stages for system improvements (Moran,
Burson, and Conrad 2017). The clinical issue being assessed was the need to increase coverage
for HPV vaccines aimed at patients meeting eligibility criteria and reducing the missed
opportunities for vaccine initiation for those qualified patients seeking healthcare within the
NMHC.
The community, employees, and educational institution are the stakeholders that trust and
hold the NMHC accountable in that the care being provided correlates with the educational
institute’s established mission statement. The NMHC is also responsible for adhering to the
recommended standards of care guidelines that are in place for delivering safe and evidencebased healthcare for the population of patients being served within this organization. The
population of patients rely on the institution to provide the necessary care that is being sought for
their goals of safe, affordable, and quality healthcare. The individuals seeking healthcare at the
NMHC have varied levels of healthcare needs.
The wide age range of patients which are serviced throughout this NMHC span from
infant to ninety-years of age, with a predominance of Hispanic, Spanish-speaking patients. Table
1 provides a pre-intervention example of the individuals seeking and receiving healthcare
services at this NMHC within a given three-month period.
Table 1
Estimated Age Distribution of Pre-Intervention Patients (n = 248)
Characteristic
Infant to 8 yrs. old
9 to 14 yrs. old
15 to 26 yrs. old
>26 yrs old
Total

Frequency

Percent

39
39
41
129
248

15.7
15.7
16.5
52.0
100.0
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The patients’ healthcare needs being met through the NMHC include Texas Health Steps
well-child examinations, sports physicals, and immunization services for adherence aimed at the
recommended Centers for Disease Control and Prevention (CDC) 2017 immunization schedule
(2017e). The immunization service requested may be for fulfilling the state mandated
recommended immunizations for school attendance and/or day-care attending purposes, as well
as satisfying immigration vaccine requirements. The NMHC works in conjunction with several
different programs geared towards helping individuals reach their healthcare goals, which may
include resources used for referral services.
Readiness for Change
The NMHC s staff was provided with a Micro-Assessment Tool (Nelson, Bataldan,
Godfrey, & Lazar, 2011) to evaluate their readiness for change and staff’s viewpoint on their
present performance throughout the NMHC pre-intervention time frame. The information
obtained from six returned MATs indicated a need and desire for providing care directed to a
community and market focus, evaluating performance results, and utilizing an integration of data
from patients, providers, as well as staff.
The NMHC’s readiness for change was evident among the provider’s and professional
staff. The three doctoral and the one master’s prepared providers, along with the doctoralprepared pharmacist and registered nurse understood and agreed with the importance aimed
towards increasing the HPV vaccine rates for this organization’s population of eligible patients.
When talking with these professionals, their eagerness to begin a quality improvement project
aimed at HPV vaccine rates was evident and well received, along with their buy-in of working
with the set of measures to ensure improvements target HPV vaccine rates. The NMHC staff’s
cooperation and agreement to incorporate the culturally sensitive educational resources can be a
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factor in generating a positive outcome in the startup of the quality improvement project
(Cassidy et al., 2014). These highly educated professionals all agreed that the fundamental task
of starting up the HPV vaccine project would play a significant role in meeting the aim of
decreased cervical, anal, as well as oral HPV infections (Beachler et al., 2015).
Table 2 displays detailed information regarding the educational accomplishments and
licensures for the Nurse Managed Health Center personnel, who are involved in delivering the
healthcare being sought.
The professional staff are highly educated and recognize the importance of increasing
vaccine rates among the eligible population of patients meeting criteria within the NMHC. The
NMHC provides children with Texas Health Steps examination, as well as immunizations. The
adults in this low-income community are also offered immunization services. This is an essential
service that the NMHC provides for this vulnerable population of patients; recognizing that
increasing the immunization rates can reduce the incidences of immunization-preventable
diseases that are linked with morbidity and mortality, such as HPV infections. The NMHC’s
offered services, place it as a prime candidate for implementing this quality improvement project
(Healthy People 2020, 2017a).
Project Identification
Purpose
The purpose of this quality improvement project was to reduce the missed opportunities
by 40% for HPV vaccines initiation in girls and boys nine to twenty-six-year-old men and
women seeking healthcare at the NMHC and improve HPV vaccine initiation rates to 80%.

DECREASE MISSED OPPORTUNITIES FOR HPV VACCINE
Table 2
NMHC Providers With Degrees, Licenses, and Certification
Healthcare Providers

Degrees

Physician

Doctor of Medicine (MD)

Clinical Director-Family

Doctor of Philosophy in Nursing (PhD) (Registered Nurse

Nurse Practitioner

(RN), Family Nurse Practitioner (FNP)-Board Certified (BC)

Family Nurse Practitioner

Doctor of Nursing Practice (DNP), Master of Science in
Nursing (MSN), RN, FNP

Family Nurse Practitioner

PhD, Registered Nurse (RN), FNP-Board Certified (BC)

Family Nurse Practitioner

MSN, RN, FNP-BC

Pharmacist

Doctor of Pharmacy (Pharm. D).

Registered Nurse

Doctor of Public Health (DrPh), MSN, RN, Public Health
Nursing Association (PHNA)-BC

Family Nurse Practitioner,

BSN, RN

Doctor of Nursing Practice
Student.
Student Seeking FNP, DNP
degree
Pharmacist Student

Seeking Pharmacy degree

Under-Graduate Nursing

Seeking Bachelor of Science in Nursing Degree (BSN)

Student
Administrative Assistant

Experience in office work.
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Objectives
The need to increase HPV vaccine rates for the patient population meeting the set criteria
is crucial, as the HPV vaccine has demonstrated efficacy against HPV type cancers (Saraiya et
al., 2015). Therefore, the aim of this project was to increase the HPV vaccine rates by 40%
among the eligible patient population within the NMHC. The objectives were focused on
reducing the missed opportunities for HPV initiation. A missed opportunity was defined as each
encounter with an eligible vaccine patient that resulted in an unvaccinated status (Mayne et al.,
2014).
Baseline data for the project were gathered from a retrospective study, conducted from
October 1, 2016 to December 31, 2016, of patients’ hardcopy charts seeking healthcare from the
NMHC. The pre-intervention information data for the NMHC indicated the need to increase the
HPV vaccine rates in eligible patients meeting set age requirements per Centers for Disease
Control and Prevention, (2017f) guideline measures. The following objectives were established:


All eligible patients would be assessed using the QPP.



The QPP tool would be applied as an element of the patient appointment.



All staff would receive training on the QPP.

Anticipated Outcomes
The anticipated outcomes for the QI project were to (a) reduce missed opportunities for
qualified HPV patients using provider focus intervention, (b) increase HPV vaccine initiation
rates for NMHC, (c) increase strong, consistent provider recommendations, (d) increase qualified
patients’ HPV vaccine facts with recommended evidence-based educational material in the
patient’s preferred language (English or Spanish), and (e) increase reminder card strategy for
return of HPV qualified patients. Therefore, the incorporation of these outcomes can correspond
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towards increasing HPV immunization rates in the NMHC (Cassidy et al., 2014; Perkins et al.,
2015; Rahman et al., 2015).
Summary and Strength of the Evidence
The HPV vaccine can be used to protect an individual from the oncogenic forms of HPV
most frequently associated with precancers and cancers linked with cervical, vaginal, vulvar,
plus anal malignancies; along with HPV forms 6 and 11 identified in causing most genital warts.
Yet, in the United States, the HPV vaccine initiation stands below the goal of Healthy People
2020 recommendation of 80% coverage (Centers for Disease Control and Prevention, 2017b;
2016a).
The evidence indicates that interventions centered on provider’s recommendations of:


Initiating the HPV vaccine for eligible patients,



Along with providing education,



As well as responding to individualized questions, and



Having reminder strategies in place,

remain as the key factors in generating continual progression for HPV immunization rates
(Cassidy et al., 2014; Perkins et al., 2015; Rahman et al., 2015)
NMHC’s interaction with the patient population seeking immunizations for various
reasons, places it at a crucial point of care. This position can play a role in the recommendation
and initiation of the HPV vaccine for individuals meeting the set criteria of the HPV vaccine,
therefore supporting the increase of HPV vaccine startup.
Evidence Strength
Perkins et al. (2015) initiated a Performance Improvement Continuing Medical Education
(PI CME) project connected with factors used widely to enhance provider practice. The project
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included startup strategies aimed at improving provider compliance for best practice guidelines
involving personalized education and feedback. These tactics were also paired with Centers for
Disease Control and Prevention’s Assessment-Feedback-Incentive-eXchange approaches of
improving vaccine use. The combination of repeated contacts, education plus personalized
feedback, as well as strong quality enhancement incentives contributed to a prospective
production of maintaining improvements in HPV immunization rates (Perkins et al., 2015).
Initiation of the HPV immunization at a younger age (9 to 10 years-old), is linked with
increased prevalence of on-time completed vaccinations compared with uptake in 11-year-olds to
12 years-olds (St. Sauver et al., 2016; Warner, 2015;). Addressing the appropriate age to initiate
and complete the HPV vaccine series is important in that the HPV vaccine’s efficacy is greatest
before initiating sexual activity and among individuals not previously exposed to HPV (Hansen,
Credle, Shapiro, & Niccolai, 2016; St. Sauver et al., 2016). The Advisory Committee on
Immunization Practices has recommended the HPV vaccine for persons 9 years of age.
Additionally, evidence indicates a stronger immune response is linked with earlier age startup of
HPV immunizations (Hansen et al., 2016; St. Sauver et al., 2016).
The evidence also supports the importance of provider recommendations as an effective
method in recommending, initiating, and completing the HPV vaccine for adolescent male and
female children. Rahman et al. (2014) reported that while parental HPV vaccine awareness was
important to uptake and completion rates, the connection involving HPV immunization
awareness plus HPV immunization initiation was associated to the provider’s recommendation.
Therefore, considerations aimed at increasing the provider’s recommendation could stimulate
improvements aimed at startups for HPV vaccinations and dose completion.
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The literature points to the importance of education for initiating the HPV vaccine in
eligible patients in addition to a reminder system (Cassidy et al., 2014; Perkins et al., 2015;
Warner et al., 2015). An implemented quality improvement study by Cassidy et al. (2014) was to
validate the use of an evidence-based educational pamphlet, along with a reminder system for
increasing the HPV immunization initiation and dose series completion. The use of a quasiexperimental design with a sample of qualifying parents of teen females from the study’s private
pediatric clinic’s database was used for this study. The results showed that HPV vaccine uptake
did improve once parental concerns, such HPV education, cost, and side effects of the HPV
vaccine had been addressed, along with the use of patient reminders. This quality improvement
initiative conducted by Cassidy et al. (2014) highlights the importance of educating the parents
and/or guardians, and patients on the facts of the HPV vaccine through evidence-based
educational resources, along with patient reminders to improve and increase HPV vaccine rates.
The findings indicate the importance of having providers recommend the HPV vaccine,
along with educating and answering any question and/or concerns for the parents and/or
guardians, in patients eligible for the HPV immunization. Offering evidence-based literature in
the culturally and linguistically appropriate language for patients, along with providing reminder
strategies for the patients that have initiated the HPV vaccine are key in helping to increase the
HPV vaccine rates. These methods and approaches were incorporated in the quality
improvement project for the NMHC.
The NMHC services a large portion of Hispanic Spanish-speaking patients, so it is key
that the evidence-based resource materials are culturally as well as linguistically suitable for this
population. The accessibility of individualized, culturally appropriate materials can increase
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conversation between the patients and staff and promote feedback from linguistically diverse
staff within the NMHC (Warner et at., 2015).
Methods
Project Plan Intervention
The period of October 1, 2016, to December 31, 2016, was the time frame designated for
pre-intervention data collection. A chart review was conducted to identify a pre-intervention
baseline for HPV vaccine initiation and missed opportunities of the eligible patients seen within
the NMHC during this period. The information was assessed using the Statistical Package for the
Social Sciences. Descriptive statistics were obtained for an overview of the missed opportunities
of HPV initiation in the NMHC during this time.
At this stage, the providers were informed of the baseline data and a plan for a QI project
targeting the reduction of missed opportunities for HPV eligible patients seeking healthcare in
the NMHC began to take shape. The intervention would focus on consistent provider
recommendations, evidence-based educational resources (in either English or Spanish language),
education for parents and young adults, plus individualized feedback, along with the use of a
reminder card system, all aimed at increasing the HPV vaccine rates for the clinic (Cassidy et al.,
2014; Hansen et al., 2016; Perkins et al., 2015; Rahman et al., 2015).
The QPP tool was designed to capture a patient’s age, the determining factor of
eligibility for HPV vaccine, per the Centers for Disease Control and Prevention’s immunization
recommendations Centers for Disease Control and Prevention, 2017e). A neon color-coding cue
of eligibility was another important element of the QPP. Green (eligible) and orange (not
eligible) neon color scheme sheets were selected because they would stand out among the
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standard white sheet documents within the patient record, thus cueing providers of the patient’s
current eligibility status for the HPV vaccine.
Therefore, having this QPP tool in place would support an intervention aimed at having a
consistent provider recommendation for patients meeting HPV vaccine criteria with the hope that
missed opportunities would be decreased among patients seeking healthcare at the NMHC
contribute to increased HPV vaccine rates for the NMHC (Perkins et al., 2015; Rahman et al.,
2015).
The Doctor of Nursing Practice Family Nurse Practitioner student met with the city’s
health department expert on immunization and coordinated an in-service presentation for the
NMHC’s providers and staff on May 29, 2016. In addition to this training, the clinic staff were
provided with examples of the QPP tool in both neon-green and neon-orange and given detailed
instructions on its use as the primary element of the project for reducing missed opportunities of
eligible HPV vaccine patients. The clinic staff and providers were also given examples of the
evidence-based educational resources in both English and Spanish, along with how the reminder
cards can help support the QI project. The providers and staff were given an opportunity to make
suggestions, ask questions and receive clarification pertaining to the use of the QPP forms,
educational materials, and the reminder card approach.
The primary element of the entire project was the implementation and use of the QPP
tool to identify eligible patients, act as reminder for the providers to recommend the HPV
vaccination series when appropriate, and ensure follow-through with the immunization, and as
well as follow-up visit(s) to complete the series.
Intervention Steps
The project included the following elements:
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Once the patient registered into the clinic at the security guard’s desk, the information
was immediately seen on the computer screen of the NMHC Administrative Assistance
(AA). The patient’s age (qualifying factor for vaccination eligibility between 9 to 26
years of age) was then verified.



The AA or available staff spoke with the patient and verified the needed service and
appropriate paperwork, either English or Spanish, and presented it to the patient on a clip
board, with instructions for the patient to fill out any necessary elements.



The QPP tool corresponding to the patient’s age at the time of the visit was completed.



The QPP tool in neon-orange represented that a patient did not meet the age for the HPV
vaccine initiation on this visit, but the form captured the patient’s age type of visit, and
reason that they did not qualify for the HPV vaccine, with age being the identifier for not
qualifying.



The QPP tool in neon-green represented a patient did meet the age for the HPV vaccine
initiation on this visit, the patients’ preferred language was verified for the appropriate
evidence-based resource material, for both parents and young adults.



The AA checked the patient’s current HPV immunization status in the city’s
Immunization Repository System, and if the patient had already started the HPV vaccine
series, then onset date was verified, and the patient was offered the next scheduled HPV
vaccine dose corresponding to their time schedule as per Centers for Disease Control and
Prevention immunization schedule 2017 (Centers for Disease Control and Prevention,
2017d, 2017e).



Then the QPP tool with input data, plus the age and language appropriate educational
material and Vaccine Information Statement (VIS) (Immunize Act Coalition, 2017), a
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reminder strategy card was paper clipped together and placed vertically within the
patient’s horizontal paperwork on the clip board.


The clipboard was then ready for the provider and the point of care interaction, at which
time the provider recommended the vaccination if the patient was eligible, ensured the
patient and parent received the educational resources, VIS, and answered any questions
or concerns the patient or parent might have at that time.



At this given opportunity, the patient decided to receive or decline the HPV vaccine.



If declination was vocalized, any additional questions or concerns were addressed by the
provider, along with encouragement to review the educational resources and
recommendation of initiating the HPV vaccine.



If the patient received the HPV vaccine, the provider would verify any allergies, allergic
reactions to vaccines and inform the patient of side-effects. Any questions or concerns the
patient had were addressed by the provider.



Then the provider proceeded to the administration of the HPV vaccine element of the
QPP, and a verbal reminder plus a reminder card were provided for the patient for their
next scheduled HPV vaccine dose.



The patient was then escorted by the provider back to the AA, where the patient was then
processed for this visit and the services provided.



The AA then extracted the QPP form from the patient’s documents and the principal
investigator kept the QPP forms as part of the QI documents.
The NMHC also works with the Vaccine for Children Program, which guarantees that

providers will have vaccines accessible free of charge, so that children meeting the set measures
for eligibility can be immunized and protected from illness that are vaccine-preventable (Texas
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Department of State Health Services, 2017a). The Adult Safety Net Program is another service
program which the NMHC works with and that also provides vaccines, which are publicly-paid
for adults aged 19 years and older who have no health insurance. These Adult Safety Net costfree vaccines increase access and delivery of immunization services to adults lacking health
insurance, thus helping to reduce or eliminate preventable illnesses (Texas Department of State
Health Services, 2017b).
The choice to implement the QI project in the above-mentioned manner was discussed
with the advisor and the mentor, then proceeded to presentation to the NMHC coordinator,
providers, and clinic staff. Everyone agreed on the process for the QPP tool’s smooth
implementation in the patient process routine. The process was implemented as planned without
deviation.
Setting and Population
The project setting was a NMHC providing healthcare services to a vulnerable population
of children, adolescents, and adults. The facility is located in a major metropolitan city in the
southwestern United States. It has one physician, one clinic director/ nurse practitioner, three
additional nurse practitioners, one pharmacist, one registered nurse, and an administrative
assistant. The NMHC also allows students from nursing and pharmacy programs to carry out
their clinical rotations within the facility.
Barriers
The organizational barriers noted were the days and time that the NMHC was open for
services. The current clinic schedule is Monday and Wednesday from 9:00 am to 1:00 pm; and
Friday 9:00 a.m. to 4:30 p.m. The NMHC operates on a part-time basis, but the need for services
is growing and may require full-time coverage.
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Another barrier was patients’ lack of knowledge about the NMHC and the services
offered. Such as its availability to offer low cost immunizations, through resources like Vaccine
for Children and Adult Safety Net vaccine programs, for patients meeting criteria. The concerns
over maintaining appropriate vaccine levels could be another barrier for this NMHC. An
additional obstacle was the clinic’s location, which patients may have not been familiar with.
Facilitators
The facilitators are the highly educated providers and staff, along with their ability to
utilize the Vaccine for Children and Adult Safety Net immunization programs that provide
vaccine assistance to qualifying patients. Additional facilitators are the meso-system that
supports the work being done by this NMHC for this community. The collaboration with city
programs, such as head-start programs, out-reach services providing vaccines at health
promotion events through the city, local school districts teaming up with the outreach
immunization services provided by the NMHC are vital.
Ethical Considerations
The ethical considerations for this quality improvement project were limited. The plans
for the project included elements to maintain patient confidentiality. The QPP tool was designed
to capture data needed for the study results but it did not contain any patient identifiable
information beyond a birth date. Following immunization, information was placed into the city
immunization repository system, thus providing an up-to-date HPV vaccine information for any
clinic needing to verify a patient’s vaccine status. All data collected for the purposes of the study
were maintained in a password protected dataset. All data were de-identified.
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Results
The study sample included all patients seen at the NMHC during the period of the
intervention. The entire sample was 334 patients ranging in ages from 1 to 26 years of age. Table
3 provides a breakdown of ages and other demographic information. The sample was fairly even
in gender distribution with males making up 47.9% of the sample and females 50.3%. So, when
assessing language preference, the patients’ preferred language (English versus Spanish) was a
50% split. In terms of the reasons given for the scheduled visit for those seeking healthcare at the
NMHC, 4% of the visits were for physicals, 57% for immigration vaccines, 18% for school
vaccines, and 20% were seen for wellness visits (Table 3).
Table 3
Characteristics of Study Sample (n=334)
Characteristic
Age Category
1 - 8 yrs
9 - 14 yrs- (HPV vaccine eligible- 2-dose series)
15 - 26 yrs- (HPV vaccine eligible- 3-dose series)
>26 yrs
Gender
Male
Female
Preferred Language
English
Spanish
Scheduled Visit Type
Physical
Immigration
Vaccine Visit
School Vaccine
Wellness

n (%)
28 (8%)
18 (5%)
119 (36%)
169 (51%)
166 (49.7%)
168 (50.3%)
167 (50%)
167 (50%)
14 (4%)
191 (57%)
61 (18%)
68 (20%)

There were 334 patients that sought care at the NMHC during the project
implementation. One-hundred percent of the eligible patients were identified and offered the
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HPV vaccine as applicable. Forty percent of the patients assessed were identified as eligible for
the HPV vaccine recommendation, and 60% of the assessed individuals did not qualify due to
age. Of the people that were qualified, 53% accepted the HPV vaccine recommendation on their
visit to the NMHC (Table 4).
Table 4
HPV Vaccine Eligibility Within Intervention (n= 334)
Characteristic
Age Category
2= 9 - 14 yrs- (HPV vaccine eligible= 2-dose series)
3= 15 - 26 yrs- (HPV vaccine eligible=3-dose series)
Gender
Male
Female
HPV Vaccine
Eligible
Non-Eligible
HPV Vaccine Offer
Accepted
Declined

n (%)

18 (5%)
119 (36%)
166 (49.7%)
168 (50.3%)
135 (40%)
199 (60%)
135 (40%)
71 (53%)
64 (47%)

A Pearson chi-square was used to assess the relationship of the likelihood of accepting
the recommendation for vaccination and whether the patient was eligible for the 2-dose or 3-dose
HPV series. There was no significant association between the dosing series (based on age) and
whether the patient accepted the recommendation of initiating the HPV vaccination series, X2 (1)
= 1.90, p = .168.
Only 35 patients received an HPV recommendation in the pre-intervention data. Onehundred and thirty-five patients received a recommendation during the intervention indicating a
55% increase in HPV vaccine recommendation. When assessing differences between pre- and
post- intervention data for acceptance of the HPV vaccine, there was a significant difference X2
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(1) = 5.33, p = .022. The percentage of patients accepting an HPV recommendation preintervention was 74% versus 53% in the post-intervention data.
When the HPV vaccine was recommended pre-intervention, there was a higher
percentage of acceptance. However, the HPV vaccine was offered at a much lower percentage
and the intervention was focused on reducing missed opportunities, not on increasing acceptance
of the HPV vaccine.
Discussion
The patients that were eligible for the HPV vaccine were identified and offered the
vaccine 100% of the time. Of those offered the vaccine, 53% accepted the recommendation and
opted to have the vaccination. However, only 85% of these individuals received the vaccination
prior to leaving the NMHC primarily due to vaccine availability. Notably, the QPP was used to
assess eligibility for every patient accessing care at the NMHC, but because the QPP focused on
evaluating eligibility based on the patient’s date of birth, it did not distinguish those individuals
that had already received the series and were therefore not eligible to receive the vaccination.
This created the large difference between those identified as being eligible and those opting to
receive the vaccination.
Additionally, acceptance rates were higher in the pre-intervention group. However, the
numbers were quite low for HPV recommendation. The focus of the QPP tool and the
intervention was on decreasing missed opportunities. The intervention increased
recommendations but additional work was needed to increase acceptance of the HPV vaccine.
The QPP tool implementation was successful due to the providers’ buy-in and
understanding the importance of offering and providing the HPV vaccine for qualifying patients.
The entire QI project was supported by the staff due to their knowledge and understanding of the
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need to prevent HPV infections. The entire staff also voiced a desire to establish clinical
indicators of care. Assessing eligibility in every patient will continue. Increasing the percentage
of vaccinations in eligible patients is an important benchmark for the NMHC.
There was difficulty in obtaining a higher vaccination numbers because of the limited
hours of operation for the NMHC. Another difficulty for implementing the program was
maintaining the necessary stock of the vaccine. Therefore, highlighting accessibility of the HPV
vaccine having been readily available once the patient had accepted the recommendation.
Admittedly, the QI project increased the offering of the vaccination and therefore the possibility
of increased vaccinations. The NMHC immunization manager will need to determine the new
demand versus supply requirements in order to meet the needs of the NMHC patient population.
It is also a possibility that providers or patients were in a time crunch that effects the ability to
thoroughly discuss the vaccination and/or receive the vaccination requirements. The QPP tool
and the implementation process streamlined the evaluation, recommendation and education
process. As the QI project evolved, the staff became very efficient and comfortable at assessing
eligibility, making recommendations and answering questions related to vaccination.
The main changes observed, since the QI project implementation are that the providers
are now self-directing and identifying the patient’s age and determining the patients’ eligibility
status before receiving the complete patient paperwork and corresponding QPP tool. They are
instinctively cued to present the HPV vaccine to the qualifying patients.
The strength, again, of the QI project is the providers buy-in for implementation and also
their active participation in the project development. The providers acknowledgement of the
importance of prevention that the HPV vaccine offers for this community of patients is the true
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key to success. Another factor adding to this strength is the VFC and ASN programs that provide
the cost-free vaccines for eligible patients.
The study conducted by Perkins et al. (2015) indicated HPV vaccine rates due to a
helpful intervention that focused on the provider. A couple of the elements covered were
education and individualized feedback for patients, which aimed to help increase HPV awareness
and immunization rates. Another study targeted a goal to initiate the HPV vaccine in patients at a
younger age (ages 9-10 years), due to a relevance of higher completion rates within this age
category (St. Sauver et al., 2016). Provider recommendations linked with parent’s understanding
of HPV, as well as the importance of completing the HPV immunizations in adolescent children
in the United States was also found to be key for increase HPV vaccination rates (Rahman et al.,
2015).
The use of the QPP tool focused on cueing providers for consistent recommendations for
initiating the HPV vaccine, with evidence-based educational resources in appropriate languages,
and personalized feedback for parents and patients understanding of HPV and the HPV vaccine
have presented a process that can be used to help increase HPV vaccine rates and completion of
dose series for patients meeting the set criteria.
Limitations
One of the limitations for this quality improvement project could be the outlined time
frame that the NMHC operates. Also, the four providers each work an individual shift, with
Friday being split into two different shifts to accommodate two different providers, one in the
morning part of the day and the second one in the afternoon. The AA is there for every shift and
the BSN, RN will also come out and help on an as needed basis. The pharmacist will also help to
the extent of her licensure. The NMHC can get busy with a stream of patients requiring different
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vaccine services. The NMHC has continued to keep providing the needed services for this
community of patients. The ability for patients to pay for services can also play a role in
limitations, along with patient time constraints and/or transportation obstacles. Another factor
can be communication barriers for Spanish speaking patients encountering a provider or staff
member who can only communicate in English. An additional limitation would be the
availability of the HPV vaccine for patients.
Recommendations
The recommendations for the quality improvement project outcomes favor the
continuation of using the QPP tool in identifying HPV vaccine qualifying patients, as well as
continuing to cue providers on offering these patients the HPV vaccine. Also, consistent
promotion of the evidence-based educational resources in appropriate languages can assist in
educating patients. Maintaining the use of the reminder card to help patients follow their HPV
vaccine series dose schedule is also an important component for program success. The NMHC
coordinator agrees that the QI project has garnered positive results and is easily sustainable. She
intends on continuing the program.
Implications for Practice
An implication of increased vaccinations is the need for a greater supply. Sadly, there
were 11 eligible patients who had accepted the HPV vaccine, but were unable to receive the
vaccine due to the lack of HPV immunization availability in the NMHC. It is unlikely that these
patients will return. These type of “misses” impact a program dedicated to decreasing missed
opportunities.
Interprofessional collaboration among the clinic coordinator, FNPs, pharmacist, and RN,
to include the AA input, would benefit the patients. The teamwork could focus on coordinating
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their strengths towards recognizing the peak times for vaccine requests and implement methods
to supply vaccines to meet demands, and therefore reduce missed opportunities with patients that
have accepted the HPV vaccine.
The NMHC provided an excellent opportunity for the DNP-FNP graduate student to
implement this QI project, due to their vaccine immunization services being provided on-site.
The immunization program fulfills various requirements such as immigration required vaccines,
state mandated vaccines for attendance, child-care immunization requirements, wellness visits,
physicals or sports physicals. The NMHC has been in place for over a year in this community
and can be trusted to provide safe standards of care for patients. The NMHC also has established
the elimination of barriers by securing in place the VFC and ASN vaccine programs for eligible
patients’ access for preventive health and wellness choices. This NMHC’s stock of
recommended vaccines to accommodate the Centers for Disease Control and Prevention’s 2017
immunization schedule, direct billing to Medicaid for their eligible patients, as well as the
providers furnishing education and addressing patients’ vaccine concerns, are all essential
elements that contribute to the success of this clinic’s continued growth and intent to promote
safe health wellness and prevention for the community that it serves.
The DNP’s role is key in evaluating, creating, and implementing an intervention that will
help a diverse population of patients reach their attainable and optimal healthcare needs.
Therefore, striving to achieve clinical prevention, which is identified as promoting health and
wellness, in addition to decreasing and/or preventing risks for individuals and families is key to
the prospective changes effecting patients’ outcomes, for improving population health. The role
of a doctoral-prepared nurse practitioner to lead project development and implementation places
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the individual as a guide, mentor, and an advocate for superior nursing practice. (American
Association of Colleges of Nursing, 2006).
Conclusion
The QI intervention was effective in decreasing missed opportunities for HPV
immunization qualified patients at the NMHC, thus helping to increase HPV vaccine rates for the
clinic, as well as the city in which this clinic resides. The city’s immunization expert indicated
that the initiation and/or completion of HPV vaccine for the NMHC patients ranging between 13
to 18 years, impacted the city’s goal to increase HPV immunization rates towards the Healthy
People 2020 goal of 80%. The city has struggled with HPV vaccination improvement rates. The
QPP tool identifies eligibility and then provides a systematic process in which eligible patients
are given recommendations and education regarding the HPV vaccine. The QI project resulted in
60 patients receiving the HPV vaccine. This an impressive number of patients given the results
QPP tool and all elements of the project process are likely to greatly improve HPV vaccination
rates.
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Appendix B

May 1 2017
PI: Ms. Maria Medina-Calvo
Protocol title: Assess the effectiveness of an intervention to decrease missed opportunities for Human
Papilloma Virus (HPV) vaccination at a nurse managed health center (NMHC).
Maria:
Your request to conduct the study titled "Assess the effectiveness of an intervention to decrease missed
opportunities for Human Papilloma Virus (HPV) vaccination at a nurse managed health center (NMHC)."
was approved by Exempt review on 05/01/2017. Your IRB approval number is 17-05-004.
Please keep in mind these additional IRB requirements:
This approval will expire one year from 05/01/2017.
Request for continuing review must be completed for projects extending past one year. Use the IRB
Continuing Review Request form.
Changes in protocol procedures must be approved by the IRB prior to implementation except when
necessary to eliminate apparent immediate hazards to the subjects. Use the IRB Amendment Request
form.
Any unanticipated problems involving risks to subjects or others must be reported immediately.
Approved protocols are filed by their number. Please refer to this number when communicating about this
protocol.
Approval may be suspended or terminated if there is evidence of a) noncompliance with federal
regulations or university policy or b) any aberration from the current, approved protocol.
Congratulations and best wishes for successful completion of your research. If you need any assistance,
please contact the UIW IRB representative for your college/school or the Office of Research
Development.
Sincerely,
Ana Wandless-Hagendorf, PhD, CPRA
Research Officer, Office of Research Development
University of the Incarnate Word
(210) 8053036
wandless
uiwtx.edu
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Appendix C
Qualified Patient Prompter (QPP)
Date

Age

9-26 (1991-2008)
Gender
Spanish

English

Vaccine Record
Reviewed
HPV Pamphlet
Provided
HPV Offered
HPV Accepted
HPV Denied
Reason:
HPV Vaccine Given
Scheduled Visit
Reason:
 Physical
 Sports Physical
Vaccine Visit
Reason:
 Immigration Requirement


School Referral



Wellness Visit

Reminder provided
Zip

Yes
New
File

No
1

2

3
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Appendix D
Non-Qualified Patient Prompter (QPP)
Date:
Age
9-26
(1991-2008)
Gender
Spanish
English
Vaccine Record
Reviewed

Yes
New
File

Scheduled Visit
Reason:
 Physical


Sports
Physical

Vaccine Visit
Immigration
Requirement
 School
Referral
 Wellness
Visit
 Reason not
qualified:
Zip

No
1

2

3

